A Study of ONO-7428 in Participants With Unresectable Advanced or Recurrent Solid Tumors

Inclusion criteria

• Participants with histologically or cytologically confirmed unresectable advanced or recurrent solid tumors.

[Backfill cohort only] Participants with histologically or cytologically confirmed Stage IIIB, IIIC, IV, or recurrent NSCLC according to UICC-TNM classification.

• Participants who are refractory or intolerant to standard therapy.
• Participants with a tumor type for which anti-PD-(L)1 antibodies have been approved and who have previously treated with anti-PD-(L)1 antibody containing regimen.
• Participants with Eastern Cooperative Oncology Group Performance Status 0 or 1.
• Participants with tumor tissue samples available for biomarker testing.

Exclusion criteria

• Participants with a complication or history of severe hypersensitivity to any other antibody drugs.
• Participants with concurrent autoimmune disease or a history of chronic or recurrent autoimmune disease
• Participants with severe peritoneal dissemination.
• Participants with pericardial fluid, pleural effusion, or ascites requiring treatment.
• Participants with uncontrolled tumor-related pain.
• Participants with active or history of interstitial lung disease or pulmonary fibrosis.